Emricasan, also known as IDN 6556 and PF 03491390, is a first-in-class caspase inhibitor in clinical trials for the treatment of liver diseases. IDN-6556 has marked efficacy in models of liver disease after oral administration and thus, is an excellent candidate for the treatment of liver diseases characterized by excessive apoptosis. IDN-6556 appears to be a feasible therapeutic agent against ischemia-reperfusion injury in liver transplantation. (Last updated: 7/7/2016).
Sun-shinechem(SSC) provides a wide range of research chemicals and biochemicals including novel life-science reagents, reference compounds, APIs, building blocks and Natural compounds for laboratory and scientific use.